Thus, if the increased level of ARMT1 due to ENALA treatment enhances DDR, the drug can have a protective effect on hypertension and related cardiovascular conditions; alternatively, the drug can also sensitize and cause an adverse effect. This evidence concerns the gene DCPH1 and hypertensive disorder.